BCM
MTNB icon

BlueCrest Capital Management’s Matinas BioPharma MTNB Stock Holding History

BlueCrest Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,557
Closed -$72K – 1216
2018
Q3 		$72K Sell
1,557
-3,388
-69% -$72.8K ﹤0.01% 1423
2018
Q2 		$107K Buy
+4,945
New +$143K ﹤0.01% 1386
2017
Q2 		– Sell
-480
Closed -$66K – 1031
2017
Q1 		$66K Buy
+480
New +$78.3K ﹤0.01% 695

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlueCrest Capital Management's MTNB Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Matinas BioPharma (MTNB) in Q4 2018, closing a stake of 1,557 shares — an estimated $72K sold.

BlueCrest Capital Management first reported a position in MTNB in Q1 2017 and held it in 3 quarters. The position peaked at $107K in Q2 2018. 35 funds tracked by Wall St. Rank hold MTNB as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Matinas BioPharma position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 1,557 Matinas BioPharma shares in Q4 2018, an estimated $72K.
  • BlueCrest Capital Management first reported a position in Matinas BioPharma in Q1 2017 and held it in 3 quarters.
  • BlueCrest Capital Management's Matinas BioPharma position peaked at $107K in Q2 2018.
  • 35 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.